Trial reportFrontiers in immunology2026
Urinary protein semi-quantification in immunochemotherapy for bladder cancer: markers of clinical outcomes.
Trial report in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open Label, Single-arm, Phase 2 Study of Perioperative Tislelizumab Combined With Nab-Paclitaxel Before Cystectomy or Complete TURBT for Patients With Muscle-invasive Urothelial Bladder Cancer.
An Open Label, Single-arm, Phase 2 Study of Tislelizumab Combined With Nab-Paclitaxel for Patients With High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: PD-1 based immunochemotherapy has improved bladder cancer (BC) outcomes, yet individual responses remain heterogeneous. Low-cost, non-invasive predictive biomarkers are urgently needed. Urinary protein semi-quantification (UPSQ) correlates with BC tumor load, but its predictive value during PD-1 based immunochemotherapy remains unclear. We conducted a Methods: 104 patients received 3 cycles of tislelizumab plus nab-paclitaxel. UPSQ at baseline (UP-B) and 60 ± 7 days (UP-60) after treatment initiation, urinary red blood cell (URBC) and urinary white blood cell (UWBC) were dynamically detected. Dynamic indices (UPDV score, UPV risk stratification) were defined to evaluate UPSQ changes. The primary endpoint was clinical complete response (cCR), and the secondary endpoints included overall survival (OS), cancer-specific survival (CSS), and events-free survival (EFS). Bulk RNA-seq transcriptomic analysis was performed in 22 MIBC patients. Results: UPSQ decreased significantly at 60 days in the overall cohort and subgroups (all p < 0.05). Baseline URBC and UWBC were positively correlated with UPSQ, while tumor size was positively associated with UPSQ in MIBC patients. In regression analyses, several indicators reached nominal significance ( Conclusions: UPSQ was linked to the clinical outcomes of patients receiving PD-1-based immunochemotherapy for BC. In MIBC, lower baseline UPSQ grade may be associated with a tumor transcriptomic phenotype contributing to better cCR and OS. Clinical Trial Registration: https://clinicaltrials.gov, identifier NCT04730219; https://clinicaltrials.gov, identifier NCT04730232.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.